期刊
ANNALS OF ONCOLOGY
卷 13, 期 5, 页码 721-729出版社
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdf063
关键词
chemotherapy; cisplatin; oesophageal cancer; quality of life; vinorelbine
类别
Background: Vinorelbine and cisplatin are active against squamous cell oesophageal carcinoma. The purpose of this phase II study was to evaluate the efficacy and safety of vinorelbine plus cisplatin in previously untreated patients with metastatic squamous cell oesophageal carcinoma and to estimate the progression-free survival, overall survival and quality of life (QoL) of the patient population. Patients and methods: Seventy-one eligible patients were entered into a study of vinorelbine 25 mg/m(2) on days 1 and 8 plus cisplatin 80 mg/m(2) on day 1, every 3 weeks. Degree of dysphagia relief was monitored and QoL was measured using the EORTC QLQ-C30. Results: All eligible patients were assessed for response and 24 achieved a confirmed partial response (33.8% 95% confidence interval 23-46); the median duration of response was 6.8 months, progression-free survival was 3.6 months and median survival of the whole group was 6.8 months. Toxicity was mainly related to neutropenia (grade 3/4 in 41% of patients). At cycle 2, 43% of the patients reported at least a moderate improvement in global health status/QoL and 25% experienced a large improvement. Conclusions: Vinorelbine plus cisplatin represents a well-tolerated active palliative regimen for patients with advanced squamous cell carcinoma of the oesophagus. This combination may offer a better therapeutic index than cisplatin-5-fluorouracil.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据